Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma

被引：77

作者：

Liao, CA

Lee, CM

Wu, HC

Wang, MC

Lu, SN

Eng, HL

机构：

[1] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Liver Unit, Kaohsiung 83305, Taiwan

[2] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Haematol, Kaohsiung 83305, Taiwan

[3] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Pathol, Kaohsiung 83305, Taiwan

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 116卷 / 01期

关键词：

hepatitis B reactivation; chemotherapy; lamivudine; lymphoma;

D O I：

10.1046/j.1365-2141.2002.03239.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chemotherapy for non-Hodgkin's lymphoma (NHL) patients with chronic hepatitis B virus (HBV) infection may be accompanied by severe hepatitis. Of 86 consecutive NHL patients, 11 (12.8%) exhibited a positive serum HBsAg. Six of these patients (54.5%) developed acute exacerbation of chronic HBV infection following chemotherapy and received lamivudine. Five of the six patients demonstrated a clinical improvement, one patient died from fulminant hepatic failure owing to delayed lamivudine therapy and poor compliance, These data suggest that HBsAg screening is necessary before commencing chemotherapy for NHL patients in a hyperendemic area and that lamivudine is effective in treating hepatitis B reactivation during chemotherapy.

引用

页码：166 / 169

页数：4

共 15 条

[1] Prevention of hepatitis B flare-up during chemotherapy using lamivudine:: case report and review of the literature [J].